TRC Cap­i­tal's mi­ni-ten­der of­fer ir­ri­tates a flus­tered Bio­gen

TRC Cap­i­tal’s trade­mark mi­ni-ten­der of­fer strat­e­gy has peev­ed an ane­mic Bio­gen, which is still lick­ing its wounds fol­low­ing the cat­a­stroph­ic fail­ure of its Alzheimer’s drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER